Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160049/S027

Stellarex 0.035 OTW Drug-Coated Angioplasty Balloon

The Spectranetics Corp. · Decision date Nov 24, 2025

FDA DECISIONP160049/S027

What did the FDA approve?

FDA records P160049/S027 as a supplement to PMA P160049, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Nov 24, 2025.

FDA approval order statement

for the implementation of an alternative paclitaxel active pharmaceutical ingredient utilized in the drug coating of the Stellarex 0.035" OTW Drug-coated Angioplasty Balloon
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Nov 24, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P160049/S027
Regulatory pathway
PMA supplement
Product code
ONU
Decision code
APPR
Decision date
Nov 24, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug-Eluting Peripheral Transluminal Angioplasty Catheter.

Product code
ONU
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P160049/S027 received

    Application receipt date recorded by FDA.

  2. P160049/S027 · FDA decision

    Normal 180 Day Track

  3. P160049/S028 · Related supplement

    Stellarex 0.035 OTW Drug-Coated Angioplasty Balloon

Timeline entries are records held by MedtechLedger for P160049. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160049

Product / regulatory recordCompanyPathwayDecision dateSource
The Spectranetics Corp.PMA supplementMar 19, 2026FDA

Explore the linked device profile

Other records with product code ONU

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

The Spectranetics Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6531 Dumbarton Cir., Fremont, CA, 94555

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records